Cargando…

Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes

BACKGROUND: In 2015, Zimbabwe introduced third-line antiretroviral therapy (ART) through four designated treatment centers; three government clinics in Harare and Bulawayo, and Newlands Clinic (NC), operated by a private voluntary organization in Harare. We describe characteristics of patients recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Chimbetete, Cleophas, Shamu, Tinei, Keiser, Olivia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051055/
https://www.ncbi.nlm.nih.gov/pubmed/32119663
http://dx.doi.org/10.1371/journal.pone.0228601
_version_ 1783502703388786688
author Chimbetete, Cleophas
Shamu, Tinei
Keiser, Olivia
author_facet Chimbetete, Cleophas
Shamu, Tinei
Keiser, Olivia
author_sort Chimbetete, Cleophas
collection PubMed
description BACKGROUND: In 2015, Zimbabwe introduced third-line antiretroviral therapy (ART) through four designated treatment centers; three government clinics in Harare and Bulawayo, and Newlands Clinic (NC), operated by a private voluntary organization in Harare. We describe characteristics of patients receiving third line ART and analyzed treatment outcomes in this national programme as of 31 December 2018. METHODS: We described the population using proportions for categorical variables, and medians and interquartile ranges for continuous variables. Patients from NC, where data were more complete, were followed from the date of starting third-line ART until death, transfer, loss to follow up or 31 December 2018. RESULTS: A total of 209 patients had ever received third-line ART: 124 at NC and 85 from the three government clinics. HIV genotype results were available for 89 (72%) patients at NC and fourteen (16.5%) patients in the government clinics. Median duration of third line ART (years) in the government clinics was 2.3 (IQR:0.6–3.4), 1.3 (IQR: 0.7–1.7) and 1 (0.6–1.9). Of the 67 patients who received third line ART in the government clinics for at least six months, 53 (79%) had most recent viral load (VL) < 1000 copies/ml. Data on other treatment outcomes from government clinics were incomplete. From NC: a total of 109 (88%) patients were still in care, 13 (10.5%) had died and 2 (1.5%) were transferred. Median duration of third-line ART was 1.4 years (IQR: 0.6–2.8). Among the 111 NC patients who had received third-line ART for at least 6 months, 83 (75%) had a VL <50 copies/ml and 106 (95.5%) had a VL <1000 copies/ml. CONCLUSION: Our findings demonstrate that, with comprehensive care, patients failing second-line ART can achieve high rates of virological suppression on third-line regimens. There is need to decentralize the provision of third-line ART in Zimbabwe. More needs to be done to improve completeness of data in the government clinics.
format Online
Article
Text
id pubmed-7051055
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-70510552020-03-12 Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes Chimbetete, Cleophas Shamu, Tinei Keiser, Olivia PLoS One Research Article BACKGROUND: In 2015, Zimbabwe introduced third-line antiretroviral therapy (ART) through four designated treatment centers; three government clinics in Harare and Bulawayo, and Newlands Clinic (NC), operated by a private voluntary organization in Harare. We describe characteristics of patients receiving third line ART and analyzed treatment outcomes in this national programme as of 31 December 2018. METHODS: We described the population using proportions for categorical variables, and medians and interquartile ranges for continuous variables. Patients from NC, where data were more complete, were followed from the date of starting third-line ART until death, transfer, loss to follow up or 31 December 2018. RESULTS: A total of 209 patients had ever received third-line ART: 124 at NC and 85 from the three government clinics. HIV genotype results were available for 89 (72%) patients at NC and fourteen (16.5%) patients in the government clinics. Median duration of third line ART (years) in the government clinics was 2.3 (IQR:0.6–3.4), 1.3 (IQR: 0.7–1.7) and 1 (0.6–1.9). Of the 67 patients who received third line ART in the government clinics for at least six months, 53 (79%) had most recent viral load (VL) < 1000 copies/ml. Data on other treatment outcomes from government clinics were incomplete. From NC: a total of 109 (88%) patients were still in care, 13 (10.5%) had died and 2 (1.5%) were transferred. Median duration of third-line ART was 1.4 years (IQR: 0.6–2.8). Among the 111 NC patients who had received third-line ART for at least 6 months, 83 (75%) had a VL <50 copies/ml and 106 (95.5%) had a VL <1000 copies/ml. CONCLUSION: Our findings demonstrate that, with comprehensive care, patients failing second-line ART can achieve high rates of virological suppression on third-line regimens. There is need to decentralize the provision of third-line ART in Zimbabwe. More needs to be done to improve completeness of data in the government clinics. Public Library of Science 2020-03-02 /pmc/articles/PMC7051055/ /pubmed/32119663 http://dx.doi.org/10.1371/journal.pone.0228601 Text en © 2020 Chimbetete et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Chimbetete, Cleophas
Shamu, Tinei
Keiser, Olivia
Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes
title Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes
title_full Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes
title_fullStr Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes
title_full_unstemmed Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes
title_short Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes
title_sort zimbabwe’s national third-line antiretroviral therapy program: cohort description and treatment outcomes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051055/
https://www.ncbi.nlm.nih.gov/pubmed/32119663
http://dx.doi.org/10.1371/journal.pone.0228601
work_keys_str_mv AT chimbetetecleophas zimbabwesnationalthirdlineantiretroviraltherapyprogramcohortdescriptionandtreatmentoutcomes
AT shamutinei zimbabwesnationalthirdlineantiretroviraltherapyprogramcohortdescriptionandtreatmentoutcomes
AT keiserolivia zimbabwesnationalthirdlineantiretroviraltherapyprogramcohortdescriptionandtreatmentoutcomes